Novel targeted agents for the treatment of advanced breast cancer-Reference-Cited by-同舟云学术

Novel targeted agents for the treatment of advanced breast cancer

Published:2012-05 Issue:7 Volume:4 Page:893-914
ISSN:1756-8919
Container-title:Future Medicinal Chemistry
language:en
Short-container-title:Future Medicinal Chemistry

Author:

de la Vega Máximo¹,Díaz-Cantón Enrique¹²,Alvarez Ricardo H³

Affiliation:

1. Fundaleu, Fundación para Combatir la Leucemia, Angélica Ocampo, Servicio de Oncología Clínica, Buenos Aires, Argentina

2. Centro de Educación Médica e Investigaciones Clínicas ‘Norberto Quirno’, Buenos Aires, Argentina

3. MD Anderson Cancer Center, Department of Breast Medical Oncology, The University of Texas, 1155 Herman Pressler, CPB5.3458, Houston, TX 77030-3721, USA.

Abstract

The discovery of the molecular processes involved in cancer development has led to the design of an array of targeted agents. These agents, directed to specific proteins in the machinery of cancer cells, interfere with vital cascades involved in cell invasion, metastasis, apoptosis, cell-cycle control and angiogenesis. In breast cancer, the main pathways studied and targeted by drugs are the HER2 pathway, EGFR, VEGF, PI3K/Akt/mammalian target of rapamycin (PI3K-M-Tor), IGF/IGFR, poly(ADP ribose) polymerase 1, HDAC and many others. In this review, we present the most promising studies of these new targeted therapies and novel combination of targeted therapies with cytotoxic agents for the treatment of breast cancer patients.

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

http://www.future-science.com/doi/pdf/10.4155/fmc.12.45

Reference150 articles.

1. Untangling the ErbB signalling network

2. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling

3. Signal Transduction through MAP Kinase Cascades

4. Specificity within the EGF family/ErbB receptor family signaling network

5. Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy;Cell Communication and Signaling;2024-07-15

2. Synthesis and Anticancer Properties of Novel Truncated Carbocyclic Nucleoside Analogues;Anti-Cancer Agents in Medicinal Chemistry;2019-01-23

3. The synergistic effect of 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-glucoside combined with Adriamycin on MCF-7 breast cancer cells;Drug Design, Development and Therapy;2018-11

4. FoxM1 is a promising candidate target in the treatment of breast cancer;Oncotarget;2017-12-12

5. Trastuzumab subcutáneo en el tratamiento del cáncer de mama HER2 positivo;Oncología Clínica;2016-03-15